Evidence map›Paper›PMID 24525279›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2014

Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells.

Marie Bleakley, Shelly Heimfeld, Lori A Jones, Cameron Turtle, Diane Krause, Stanley R Riddell, Warren Shlomchik

3 registry-linked trialsOpen access · hybridAbstract read
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 61 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 2 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02337595 phase1 / phase2completednot on this map

Transfusion of CD45RA-depleted Donor Lymphocytes to Improve Regeneration of Antimicrobial Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation

TypeinterventionalSponsorFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyRan2014 to 2016Enrolled30ConditionsPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Immune Deficiency Disease, Bone Marrow Failure SyndromesArmsCD45RA-depleted peripheral blood mononuclear cells
NCT03810196 narecruitingnot on this mapstarted 2019, after this paper: background citation

CD45RA Depleted Peripheral Stem Cell Addback for Patients at Risk for Viral or Fungal Infections Post TCRαβ/CD19 Depleted Hematopoietic Stem Cell Transplant

TypeinterventionalSponsorChildren's Hospital of PhiladelphiaRan2019 to 2028Enrolled50ConditionsAcute Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic LeukemiaArmsCliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback
NCT06839456 phase1 / phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Phase 1/2 Study: CD45RA Depleted Peripheral Stem Cell Addback to Prevent Viral and Fungal Infections Following Alternative Donor TCRab/CD19 Depleted Hematopoietic Stem Cell Transplant

TypeinterventionalSponsorChildren's Hospital of PhiladelphiaRan2025 to 2032Enrolled100ConditionsLeukemia, High Risk Acute Lymphoblastic Leukemia, High Risk Acute Myeloid Leukemia, Relapse LeukemiaArmsPhase 1 Dose Level 1, Phase 1 Dose Level 2, Phase 1 Dose Level 3, Phase 2 Maximum Tolerated Dose determined in Phase 1, Phase 2 Established Dose from prior study, NCT03810196
3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 2 syntheses or guidelines pooled it, 108 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Review
  10. "Attack!" Cellular Therapies to Attack Pathogens and Tumors.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025
    Article
  11. Article
  12. Article
  13. Incidence, severity, and temporal development of oral complications in pediatric allogeneic hematopoietic stem cell transplant patients - a multicenter study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Marie BleakleyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Pediatrics, University of Washington, Seattle, Washington. Electronic address: mbleakle@fhcrc.org.
Shelly HeimfeldClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Lori A JonesSeattle Cancer Care Alliance, Seattle, Washington.
Cameron TurtleClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington.
Diane KrauseDepartment of Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut.
Stanley R RiddellClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington.
Warren ShlomchikDepartment of Hematology, Yale School of Medicine, New Haven, Connecticut.
Fred Hutch Cancer Center · USYale University · USCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZASeattle Cancer Care Alliance · USUniversity of Washington · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
VIRUS-MEDIATED MYELOSUPPRESSIONP01CA018029 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STEPHANIE J LEE · 1985 to 2026
$128.4M
CORE--VECTOR PRODUCTIONP30DK056465 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HEIMFELD, SHELLY · 1999 to 2014
$14.9M
Targeted therapy of B cell malignances with CAR-T cells of defined compositionR01CA136551 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI JENSEN, MICHAEL C, RIDDELL, STANLEY R. · 2009 to 2018
$5.5M
Allogeneic stem cell transplant with grafts depleted of naive T cells for leukemiK23CA154532 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BLEAKLEY, MARIE · 2011 to 2015
$850k
NCI NIH HHS CA 136551NCI NIH HHS CA15704NCI NIH HHS CA18029NCI NIH HHS K23 CA154532NCI NIH HHS K23CA154532NCI NIH HHS P01 CA018029NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA136551NIDDK NIH HHS DK56465NIDDK NIH HHS P30 DK056465
6 · The paper itself

Abstract

Graft-versus-host disease (GVHD) is a frequent major complication of allogeneic hematopoietic cell transplantation (HCT). Approaches that selectively deplete T cells that cause GVHD from allogeneic stem cell grafts and preserve T cells specific for pathogens may improve HCT outcomes. It has been hypothesized that the majority of T cells that can cause GVHD reside within the naïve T cell (TN) subset, and previous studies performed in mouse models and with human cells in vitro support this hypothesis. As a prelude to translating these findings to the clinic, we developed and evaluated a novel 2-step clinically compliant procedure for manipulating peripheral blood stem cells (PBSC) to remove TN, preserve CD34(+) hematopoietic stem cells, and provide for a fixed dose of memory T cells (TM) that includes T cells with specificity for common opportunistic pathogens encountered after HCT. Our studies demonstrate effective and reproducible performance of the immunomagnetic cell selection procedure for depleting TN. Moreover, after cell processing, the CD45RA-depleted PBSC products are enriched for CD4(+) and CD8(+) TM with a central memory phenotype and contain TM cells that are capable of proliferating and producing effector cytokines in response to opportunistic pathogens.

Indexed as

Immunologic MemoryAntigens, CD34Antigens, ViralGene ExpressionHematopoietic Stem CellsHematopoietic Stem Cell TransplantationHumansImmunomagnetic SeparationImmunophenotypingLeukocyte Common AntigensLymphocyte DepletionPeptide LibraryTissue EngineeringT-LymphocytesT-Lymphocyte SubsetsAntigens, CD34Antigens, ViralLeukocyte Common AntigensPeptide LibraryGraft engineeringGraft-versus-host diseaseImmune reconstitutionMemory T cellsNaïve T cellsSelective T cell depletion

Identifiers

PMID24525279
PMCPMC3985542
OpenAlexW2093964518

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.